US4853409A - 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function - Google Patents

3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function Download PDF

Info

Publication number
US4853409A
US4853409A US07/181,142 US18114288A US4853409A US 4853409 A US4853409 A US 4853409A US 18114288 A US18114288 A US 18114288A US 4853409 A US4853409 A US 4853409A
Authority
US
United States
Prior art keywords
thienyl
pharmaceutically
acceptable base
base salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/181,142
Inventor
Henry J. Showell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Assigned to PFIZER INC., A CORP. OF DE. reassignment PFIZER INC., A CORP. OF DE. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: SHOWELL, HENRY J.
Priority to US07/181,142 priority Critical patent/US4853409A/en
Priority to DE8989303050T priority patent/DE68906707T2/en
Priority to AT89303050T priority patent/ATE89725T1/en
Priority to EP89303050A priority patent/EP0337628B1/en
Priority to PH38415A priority patent/PH25857A/en
Priority to IL8987289A priority patent/IL89872A/en
Priority to MYPI89000448A priority patent/MY103872A/en
Priority to JP1090492A priority patent/JPH01311022A/en
Priority to PT90249A priority patent/PT90249B/en
Priority to CA000596306A priority patent/CA1324762C/en
Priority to ZA892622A priority patent/ZA892622B/en
Priority to AU32712/89A priority patent/AU601326B2/en
Priority to NZ228712A priority patent/NZ228712A/en
Priority to DK174289A priority patent/DK174289A/en
Priority to IE117189A priority patent/IE62751B1/en
Priority to KR1019890004822A priority patent/KR920002328B1/en
Priority to HU891754A priority patent/HU204996B/en
Publication of US4853409A publication Critical patent/US4853409A/en
Application granted granted Critical
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Definitions

  • This invention relates to the use of certain 3-substituted-2-oxindole-1-carboxamides and the pharmaceutically-acceptable base salts thereof for suppressing T-cell function in a mammal.
  • the invention compounds and salts are useful in treating T-cell mediated autoimmune disorders.
  • Such autoimmune disorders can be systemic or organ specific and include, but are not limited to, multiple sclerosis, systemic lupus erythematosus (SLE), type I diabetes, myasthenia gravis and chronic liver disease.
  • SLE systemic lupus erythematosus
  • the use of such compounds and salts comprise administering an effective amount thereof to a mammal.
  • Certain autoimmune disorders of the systemic and organ specific type such as type I diabetes, chronic liver disease and myasthenia gravis, among others, are described in Autoimmunity: Basic Concepts; Systemic and Selected Organ Specific Diseases, Cruse, J. M. and Lewis, Jr., R. E., Eds., S. Karger, New York, 1985 at pages 51-71.
  • the role of T-cell dysfunction and certain autoimmune disorders of the systemic and organ specific type such as systemic lupus erythematosus (SLE), among others, are disclosed in Bellanti, Joseph A., Immunology III, W. B. Saunders Co., Philadelphia (1985), Chapter 20, Part C., pages 409-446. The teachings of those references are incorporated herein by reference.
  • autoimmune disorders can be systemic or organ specific and include, but are not limited to, multiple sclerosis, systemic lupus erythematosus (SLE), type I diabetes, myasthenia gravis and chronic liver disease.
  • the methods of using the compounds and their pharmaceutically-acceptable base salts comprise administering to a mammal an effective amount of such compounds.
  • Administration can comprise any known method for therapeutically providing a compound to a mammal such as by oral or parenteral administration as defined hereinbelow.
  • the compounds of this invention hereinabove described are acidic and form base salts. All such base salts are within the scope of this invention and can be formed as taught by that patent.
  • suitable salts within the scope of this invention, include both the organic and inorganic types and include, but are not limited to, the salts formed with ammonia, organic amines, alkali metal hydroxides, alkali metal carbonates, alkali metal bicarbonates, alkali metal hydrides, alkali metal alkoxides, alkaline earth metal hydroxides, alkaline earth metal carbonates, alkaline earth metal hydrides and alkaline earth metal alkoxides.
  • bases which form such base salts include ammonia, primary amines, such as n-propylamine, n-butylamine, aniline, cyclohexylamine, benzylamine, p-toluidine, ethanoline and glucamine; secondary amines, such as diethylamine, diethanolamine, N-methylglucamine, N-methylaniline, morpholine, pyrrolidine and piperidine; tertiary amines, such as triethylamine, triethanolamine, N,N-dimethylaniline, N-ethylpiperidine and N-methylmorpholine; hydroxides, such as sodium hydroxide; alkoxides such as sodium ethoxide and potassium methoxide; hydrides such as calcium hydride and sodium hydride; and carbonates such as potassium carbonate and sodium carbonate.
  • Preferred salts are those of sodium, potassium, ammonium, ethanolamine, diethanolamine and triethanolamine. Particularly preferred
  • solvates such as the hemihydrates and monohydrates of the compounds hereinabove described.
  • the method of this invention comprise administering the invention compounds and the pharmaceutically-acceptable base salts thereof to a mammal.
  • Such compounds and their salts can be administered to said mammal either alone or, preferably, in combination with pharmaceutically-acceptable carriers or diluents in a pharmaceutical composition, according to standard pharmaceutical practice.
  • Such administration can be oral or parenteral.
  • Parenteral administration as used herein includes, but is not limited to, intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal and topical administration. However, while it is generally preferred to administer such compounds and their salts orally, parenteral administration may be preferable in treating certain disorders such as chronic liver disease.
  • these compounds and their salts are most desirably administered in doses ranging from about 40 mg up to about 200 mg per day for oral administration and from about 1 mg up to about 200 mg per day for parenteral administration, although variations will still necessarily occur depending upon the weight of the subject being treated.
  • the appropriate dose for suppressing T-cell function in a mammal and for treatment of T-cell mediated autoimmune disorders with the compounds and their salts of this invention will be readily determined by those skilled in the art of prescribing and/or administering such compounds. Nevertheless, it is still to be appreciated that other variations may also occur in this respect, depending upon the species of mammal being treated and its individual response to said medicament, as well as on the particular type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out.
  • dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful or deleterious side effects to occur, provided that such higher dose levels are first divided into several smaller doses that are to be administered throughout the day.
  • tablets containing excipients such as sodium citrate, calcium carbonate and dicalcium phosphate may be employed along with various disintegrants such as starch and preferably potato to tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • disintegrants such as starch and preferably potato to tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia.
  • lubricating agents such as, but not limited to, magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes.
  • Solid compositions of a similar type may also be employed as fillers in soft elastic and hardfilled gelatin capsules; preferred materials in this connection also include, by way of example and not of limitation, lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • preferred materials in this connection also include, by way of example and not of limitation, lactose or milk sugar as well as high molecular weight polyethylene glycols.
  • the essential active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
  • the preferred mode of administration of the compounds of this invention or their pharmaceutically-acceptable base salts is oral, they may be administered parenterally as well.
  • solutions of these particular compounds in sesame or peanut oil or in aqueous propylene glycol may be employed, as well as sterile aqueous solutions of the corresponding water soluble base salts previously enumerated.
  • aqueous solutions should be suitably buffered if necessary, and the liquid diluent rendered isotonic with sufficient saline or glucose.
  • these particular aqueous solutions are especially suitable for intravenous, intramuscular and subcutaneous injection purposes.
  • the sterile aqueous media employed are readily obtained by standard techniques well known to those skilled in the art.
  • the dosage form of the particular compound may include, by way of example, solutions, lotions, ointments, creams, gels, suppositories, rate-limiting sustained release formulations and devices therefor.
  • Such dosage forms comprise the particular compound and may include ethanol, water, penetration enhancer and inert carriers such as gelproducing materials, mineral oil, emulsifying agents, benzyl alcohol and the like.
  • Specific transdermal flux enhancing compositions are disclosed in pending U.S. patent application Ser. No. 925,641, filed Oct. 31, 1986, which is assigned to the assignee of this invention, the teachings of which are incorporated herein by reference.
  • the dosage form of the particular compound may include, by way of example and not of limitation, solutions, lotions, ointments, creams and gels.
  • mice are killed at 4, 8 and 16 days post egg challenge and the lungs are inflated with 10% buffered formalin, removed prepared for histological section and stained with hematoxylin and eosin.
  • the pulmonary granuloma areas are measured from sections using an Omicron alpha image analyzer (Bausch and Lomb Inc., Rochester, N.Y.) with the data being fed into an attached computer. A minimum of 20 granulomas are measured from each lung and the granulomas from at least five mice per compound/dosage are measured.

Abstract

This invention relates to the use of certain 3-substituted-2-oxindole-1-carboxamides of the formula <CHEM> and the pharmaceutically-acceptable base salts thereof wherein X is H, Cl or F; Y is H or Cl; and R is benzyl or thienyl to suppress T-cell function in a mammal. This invention also relates to the use of such compounds for treating T-cell mediated autoimmune disorders of the systemic or organ specific type. The methods of this invention comprise administering a T-cell function suppressing amount of the compounds and salts of this invention to such a mammal.

Description

BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to the use of certain 3-substituted-2-oxindole-1-carboxamides and the pharmaceutically-acceptable base salts thereof for suppressing T-cell function in a mammal. The invention compounds and salts are useful in treating T-cell mediated autoimmune disorders. Such autoimmune disorders can be systemic or organ specific and include, but are not limited to, multiple sclerosis, systemic lupus erythematosus (SLE), type I diabetes, myasthenia gravis and chronic liver disease. The use of such compounds and salts comprise administering an effective amount thereof to a mammal.
2. General Background
Certain 3-substituted-2-oxindole-1-carboxamides of the formula ##STR2## and the pharmaceutically-acceptable base salts thereof wherein, inter alia, X is H, Cl or F; Y is H or Cl; and R is benzyl or thienyl are disclosed and claimed in U.S. Pat. No. 4,556,672 which is assigned to the assignee hereof. That patent discloses that those compounds, in addition to being useful as antiinflammatory and analgesic agents. are inhibitors of both cyclooxygenase (CO) and lipoxygenase (LO). The teachings thereof are incorporated herein by reference.
Certain autoimmune disorders of the systemic and organ specific type such as type I diabetes, chronic liver disease and myasthenia gravis, among others, are described in Autoimmunity: Basic Concepts; Systemic and Selected Organ Specific Diseases, Cruse, J. M. and Lewis, Jr., R. E., Eds., S. Karger, New York, 1985 at pages 51-71. The role of T-cell dysfunction and certain autoimmune disorders of the systemic and organ specific type such as systemic lupus erythematosus (SLE), among others, are disclosed in Bellanti, Joseph A., Immunology III, W. B. Saunders Co., Philadelphia (1985), Chapter 20, Part C., pages 409-446. The teachings of those references are incorporated herein by reference.
In copending U.S. patent application Ser. No. 181,131 entitled 3-Substituted-2-Oxindole-1-Carboxamides As Inhibitors of Interleukin-1 Biosynthesis, filed concurrently herewith and which is assigned to the assignee hereof, it is disclosed that the compounds of this invention do not inhibit lipoxygenase in the present of serum.
It has been reported that lipoxygenase metabolites play a role in T-lymphocyte mitogenesis. Baily, J. M., et al., Cellular Immunology, 67, 112-120 (1982); and Kelly, J. P., et al., J. Immunology, 122, 1563-1571 (1979). Further, certain inhibitors of cyclooxygenase have been reported to increase cell-mediated immunity, certain lipoxygenase inhibitors have been reported to inhibit cell-mediated immunity and certain cyclooxygenase and lipoxygenase inhibitors have been found to enhance cell-mediate immunity at lower concentrations and inhibit such immunity at higher concentrations. Leung, K. H., et al., Int. J. Immunopharmac., 4, 195-204 (1982).
Aspirin has been reported to suppress blastogenesis of lymphocytes. Crout, J. E., et al., N. E. J. Med., 292, 221-223 (1975). Further, IL-1 has been reported to augment T-cell activation and lymphokine release. See, Hanna, N. and Wood D. D., Adv. Inflammation Res., Vol. 12 (1988) at 11-14 and reference cited therein.
Until the invention herein, there was no report of use or intent to use the compounds or salts of this invention to suppress T-cell function independent of lipoxygenase inhibition and to treat T-cell mediated autoimmune disorders with such compounds nor any appreciation of their role in such treatments.
SUMMARY OF THE INVENTION
It has been found that certain 3-substituted-2oxindole-1-carboxamides of the formula ##STR3## and the pharmaceutically-acceptable base salts thereof wherein X is H, Cl or F; Y is H or Cl; and R is benzyl or thienyl suppress T-cell function independent of their lipoxygenase inhibiting activity and, thus, are useful in treating T-cell mediated autoimmune disorders. Such autoimmune disorders can be systemic or organ specific and include, but are not limited to, multiple sclerosis, systemic lupus erythematosus (SLE), type I diabetes, myasthenia gravis and chronic liver disease.
The methods of using the compounds and their pharmaceutically-acceptable base salts comprise administering to a mammal an effective amount of such compounds. Administration can comprise any known method for therapeutically providing a compound to a mammal such as by oral or parenteral administration as defined hereinbelow.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of this invention which are of the formula ##STR4## and the pharmaceutically-acceptable base salts thereof wherein X is H, Cl or F; Y is H or Cl; and R is benzyl or thienyl and the preparation thereof are disclosed in U.S. Pat. No. 4,556,672, the teachings of which are incorporated herein by reference. This invention concerns new uses for such compounds which comprise methods for suppressing T-cell function in a mammal independent of inhibition of lipoxygenase. Also within the scope of this invention are methods of treating T-cell mediated autoimmune disorders which can be either systemic or organ specific.
Of the methods described above, preferred therein are those where the compound employed is of the formula above wherein X is Cl, Y is H and R is thienyl; those wherein said compound X is F, Y is Cl and R is thienyl; those wherein in said compound X is F, Y is Cl and R is 2-thienyl and those wherein in said compound X is H, Y is Cl and R is benzyl. Particularly preferred are methods wherein said compound X is Cl, Y is H and R is 2-thienyl.
As disclosed in U.S. Pat. No. 4,556,672, the compounds of this invention hereinabove described are acidic and form base salts. All such base salts are within the scope of this invention and can be formed as taught by that patent. Such suitable salts, within the scope of this invention, include both the organic and inorganic types and include, but are not limited to, the salts formed with ammonia, organic amines, alkali metal hydroxides, alkali metal carbonates, alkali metal bicarbonates, alkali metal hydrides, alkali metal alkoxides, alkaline earth metal hydroxides, alkaline earth metal carbonates, alkaline earth metal hydrides and alkaline earth metal alkoxides. Representative examples of bases which form such base salts include ammonia, primary amines, such as n-propylamine, n-butylamine, aniline, cyclohexylamine, benzylamine, p-toluidine, ethanoline and glucamine; secondary amines, such as diethylamine, diethanolamine, N-methylglucamine, N-methylaniline, morpholine, pyrrolidine and piperidine; tertiary amines, such as triethylamine, triethanolamine, N,N-dimethylaniline, N-ethylpiperidine and N-methylmorpholine; hydroxides, such as sodium hydroxide; alkoxides such as sodium ethoxide and potassium methoxide; hydrides such as calcium hydride and sodium hydride; and carbonates such as potassium carbonate and sodium carbonate. Preferred salts are those of sodium, potassium, ammonium, ethanolamine, diethanolamine and triethanolamine. Particularly preferred are the sodium salts.
Also within the scope of this invention are the solvates such as the hemihydrates and monohydrates of the compounds hereinabove described.
The method of this invention comprise administering the invention compounds and the pharmaceutically-acceptable base salts thereof to a mammal. Such compounds and their salts can be administered to said mammal either alone or, preferably, in combination with pharmaceutically-acceptable carriers or diluents in a pharmaceutical composition, according to standard pharmaceutical practice. Such administration can be oral or parenteral. Parenteral administration as used herein includes, but is not limited to, intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal and topical administration. However, while it is generally preferred to administer such compounds and their salts orally, parenteral administration may be preferable in treating certain disorders such as chronic liver disease.
In general, these compounds and their salts are most desirably administered in doses ranging from about 40 mg up to about 200 mg per day for oral administration and from about 1 mg up to about 200 mg per day for parenteral administration, although variations will still necessarily occur depending upon the weight of the subject being treated. The appropriate dose for suppressing T-cell function in a mammal and for treatment of T-cell mediated autoimmune disorders with the compounds and their salts of this invention will be readily determined by those skilled in the art of prescribing and/or administering such compounds. Nevertheless, it is still to be appreciated that other variations may also occur in this respect, depending upon the species of mammal being treated and its individual response to said medicament, as well as on the particular type of pharmaceutical formulation chosen and the time period and interval at which such administration is carried out. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful or deleterious side effects to occur, provided that such higher dose levels are first divided into several smaller doses that are to be administered throughout the day.
For purposes of oral administration, tablets containing excipients such as sodium citrate, calcium carbonate and dicalcium phosphate may be employed along with various disintegrants such as starch and preferably potato to tapioca starch, alginic acid and certain complex silicates, together with binding agents such as polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as, but not limited to, magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in soft elastic and hardfilled gelatin capsules; preferred materials in this connection also include, by way of example and not of limitation, lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspension and/or elixirs are desired for oral administration, the essential active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes and, if so desired, emulsifying and/or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin and various like combinations thereof.
Although the preferred mode of administration of the compounds of this invention or their pharmaceutically-acceptable base salts is oral, they may be administered parenterally as well.
For purposes of parenteral administration, solutions of these particular compounds in sesame or peanut oil or in aqueous propylene glycol may be employed, as well as sterile aqueous solutions of the corresponding water soluble base salts previously enumerated. Such aqueous solutions should be suitably buffered if necessary, and the liquid diluent rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular and subcutaneous injection purposes. In this connection, the sterile aqueous media employed are readily obtained by standard techniques well known to those skilled in the art. For instance, distilled water is ordinarily used as the liquid diluent and the final preparation is passed through a suitable bacterial filter such as a sintered glass filter or a diatomaceous-earth or unglazed porcelain filter. Preferred filters of this type include the Berkefeld, the Chamberland and the Asbestos Disk-Metal Seitz filter, wherein the fluid is sucked into a sterile container with the aid of a suction pump. Needless to say, the necessary steps should be taken throughout the preparation of these injectable solutions to insure that the final products are obtained in a sterile condition. For purposes of transdermal administration, the dosage form of the particular compound may include, by way of example, solutions, lotions, ointments, creams, gels, suppositories, rate-limiting sustained release formulations and devices therefor. Such dosage forms comprise the particular compound and may include ethanol, water, penetration enhancer and inert carriers such as gelproducing materials, mineral oil, emulsifying agents, benzyl alcohol and the like. Specific transdermal flux enhancing compositions are disclosed in pending U.S. patent application Ser. No. 925,641, filed Oct. 31, 1986, which is assigned to the assignee of this invention, the teachings of which are incorporated herein by reference. For purposes of topical administration, the dosage form of the particular compound may include, by way of example and not of limitation, solutions, lotions, ointments, creams and gels.
The ability of the compounds to suppress T-cell function is demonstrated by the procedures of Kunkel, S. L., et al., J. Clin. Invest., 74, 514-524 (1984) which is described below.
Female CBA/J mice (The Jackson Laboratory, Bar Harbor, Maine) are maintained under standard care and given food and water ad libitum. Eggs are isolated from the livers of mice which have been previously infected with 200 cercariae of Schistosome mansoni by the method of Coker and von Lichtenberg, Proc. Soc. Exp. Biol. Med., 92, 359-364 (1956). The isolated schistosome eggs are suspended to 4,000/ml in sterile physiological saline and induction of pulmonary egg granulomas is accomplished vial tail vein injection of 2000 eggs per mouse. The compound under study is administered daily to the mouse via intraperitoneal injection after egg embolization. Dosages range from 0 to 100 mg/kg in an appropriate solvent. Mice are killed at 4, 8 and 16 days post egg challenge and the lungs are inflated with 10% buffered formalin, removed prepared for histological section and stained with hematoxylin and eosin. The pulmonary granuloma areas are measured from sections using an Omicron alpha image analyzer (Bausch and Lomb Inc., Rochester, N.Y.) with the data being fed into an attached computer. A minimum of 20 granulomas are measured from each lung and the granulomas from at least five mice per compound/dosage are measured.

Claims (40)

What is claimed is:
1. A method of suppressing T-cell function in a mammal which comprises administering to a mammal in need thereof a T-cell function suppressing amount of a compound of the formula ##STR5## or a pharmaceutically-acceptable base salt thereof, wherein X is H, Cl or F; Y is H or Cl; and R is benzyl or thienyl.
2. The method according to claim 1 wherein X is Cl; Y is H; and R is thienyl.
3. The method according to claim 2 wherein R is 2-thienyl.
4. The method according to claim 3 wherein the pharmaceutically-acceptable base salt is sodium.
5. The method according to claim 1 wherein X is F; Y is Cl and R is thienyl.
6. The method according to claim 5 wherein R is 2-thienyl.
7. The method according to claim 1 wherein X is H; Y is Cl; and R is benzyl.
8. The method according to claim 1 wherein the compound or a pharmaceutically-acceptable base salt thereof is administered orally.
9. The method according to claim 1 wherein the compound or a pharmaceutically-acceptable base salt thereof is administered parenterally.
10. A method of treating T-cell mediated autoimmune disorders in a mammal which comprises administering to said mammal a T-cell mediated autoimmune disorder treating amount of a compound of the formula ##STR6## or a pharmaceutically-acceptable base salt thereof, wherein X is H, Cl or F; Y is H or Cl; and R is benzyl or thienyl.
11. The method according to claim 10 wherein X is Cl; Y is H; and R is thienyl.
12. The method according to claim 11 wherein R is 2-thienyl.
13. The method according to claim 12 wherein the pharmaceutically-acceptable base salt is sodium.
14. The method according to claim 10 wherein X is F: Y is Cl and R is thienyl.
15. The method according to claim 14 wherein R is 2-thienyl.
16. The method according to claim 10 wherein X is H; Y is Cl; and R is benzyl.
17. The method according to claim 10 wherein the compound or a pharmaceutically-acceptable base salt thereof is administered orally.
18. The method according to claim 10 wherein the compound or a pharmaceutically-acceptable base salt thereof is administered parenterally.
19. The method of treating T-cell mediated systemic autoimmune disorders in a mammal which comprises administering to said mammal a T-cell mediated systemic autoimmune disorder treating amount of a compound of the formula ##STR7## or a pharmaceutically-acceptable base salt thereof, wherein X is H, Cl or F; Y is H or Cl; and R is benzyl or thienyl.
20. The method according to claim 19 wherein X is Cl; Y is H; and R is thienyl.
21. The method according to claim 20 wherein R is 2-thienyl.
22. The method according to claim 21 wherein the pharmaceutically-acceptable base salt is sodium.
23. The method according to claim 19 wherein X is F; Y is Cl; and R is thienyl.
24. The method according to claim 23 wherein R is 2-thienyl.
25. The method according to claim 19 wherein X is H; Y is Cl; and R is benzyl.
26. The method according to claim 19 wherein the compound or a pharmaceutically-acceptable base salt thereof is administered orally.
27. The method according to claim 19 wherein the compound or a pharmaceutically-acceptable base salt thereof is administered parenterally.
28. The method according to claim 19 wherein the systemic autoimmune disorder is multiple sclerosis or systemic lupus erythematosus.
29. The method according to claim 22 wherein the systemic autoimmune disorder is multiple schlerosis or systemic lupus erythematosus.
30. A method of treating T-cell mediated organ specific autoimmune disorders in a mammal which comprises administering to said mammal a T-cell mediated organ specific autoimmune disorder treating amount of a compound of the formula ##STR8## or a pharmaceutically-acceptable base salt thereof, wherein X is H, Cl or F; Y is H or Cl; and R is benzyl or thienyl.
31. The method according to claim 20 wherein X is Cl; Y is H; and R is thienyl.
32. The method according to claim 22 wherein R is 2-thienyl.
33. The method according to claim 32 wherein the pharmaceutically-acceptable base salt is sodium.
34. The method according to claim 30 wherein X is F; Y is Cl; and R is thienyl.
35. The method according to claim 34 wherein R is 2-thienyl.
36. The method according to claim 30 wherein X is H; Y is Cl; and R is benzyl.
37. The method according to claim 30 wherein the compound or a pharmaceutically-acceptable base salt thereof is administered orally.
38. The method according to claim 30 wherein the compound or a pharmaceutically-acceptable base salt thereof is administered parenterally.
39. The method according to claim 30 wherein the organ specific autoimmune disorder is type I diabetes, myasthenia gravis or chronic liver disease.
40. The method according to claim 33 wherein the organ specific autoimmune disorder is type I diabetes, myasthenia gravis or chronic liver disease.
US07/181,142 1988-04-13 1988-04-13 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function Expired - Lifetime US4853409A (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
US07/181,142 US4853409A (en) 1988-04-13 1988-04-13 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function
DE8989303050T DE68906707T2 (en) 1988-04-13 1989-03-28 3-SUBSTITUTED 2-OXINDOL-1-CARBOXAMIDE DERIVATIVES TO INHIBIT T-CELL ACTIVITY.
AT89303050T ATE89725T1 (en) 1988-04-13 1989-03-28 3-SUBSTITUTED 2-OXINDOL-1-CARBOXAMIDE DERIVATIVES FOR INHIBITION OF T-CELL ACTIVITY.
EP89303050A EP0337628B1 (en) 1988-04-13 1989-03-28 3-substituted-2-oxindole-1-carboxamides for suppressing t-cell function
PH38415A PH25857A (en) 1988-04-13 1989-03-31 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function
IL8987289A IL89872A (en) 1988-04-13 1989-04-06 Use of 3-substituted-2-oxindole-1- carboxamides for the preparation of pharmaceutical compositions for suppressing T-cell function
MYPI89000448A MY103872A (en) 1988-04-13 1989-04-08 3-substituted-2-oxindole-1-carboxamides for suppressing t-cell function.
JP1090492A JPH01311022A (en) 1988-04-13 1989-04-10 3-substituted-2-oxyindole-1-carboxamide for suppressing t-cell function
PT90249A PT90249B (en) 1988-04-13 1989-04-11 METHOD FOR THE USE OF 3-SUBSTITUTED 2-OXINDOLE-1-CARBOXAMIDES FOR T-CELL BLENDING
CA000596306A CA1324762C (en) 1988-04-13 1989-04-11 3-substituted-2-oxindole-1-carboxamides for suppressing t-cell function
ZA892622A ZA892622B (en) 1988-04-13 1989-04-11 3-substituted-2-oxindole-1-carboxamides for suppressing t-cell function
AU32712/89A AU601326B2 (en) 1988-04-13 1989-04-12 3-substituted-2-oxindole-1-carboxamides for suppressing t-cell function
NZ228712A NZ228712A (en) 1988-04-13 1989-04-12 3-substituted-2-oxindole-1-carboxamides for suppressing t-cell function
DK174289A DK174289A (en) 1988-04-13 1989-04-12 USE OF 3-SUBSTITUTED 2-OXINDOL-1-CARBOXAMIDE COMPOUNDS FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS FOR THE REPRESENTATION OF T-CELL FUNCTION
IE117189A IE62751B1 (en) 1988-04-13 1989-04-12 3-substituted-2-oxindole-1-carboxamides for suppressing t-cell function
KR1019890004822A KR920002328B1 (en) 1988-04-13 1989-04-12 T-cell function suppressing agent containing of 3-substituted-2-oxindole-1-carboxamides
HU891754A HU204996B (en) 1988-04-13 1989-04-12 Process for producing pharmaceutical compositions comprising 3-substituted-2-oxindole-1-carboxamide derivatives as active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/181,142 US4853409A (en) 1988-04-13 1988-04-13 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function

Publications (1)

Publication Number Publication Date
US4853409A true US4853409A (en) 1989-08-01

Family

ID=22663072

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/181,142 Expired - Lifetime US4853409A (en) 1988-04-13 1988-04-13 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function

Country Status (17)

Country Link
US (1) US4853409A (en)
EP (1) EP0337628B1 (en)
JP (1) JPH01311022A (en)
KR (1) KR920002328B1 (en)
AT (1) ATE89725T1 (en)
AU (1) AU601326B2 (en)
CA (1) CA1324762C (en)
DE (1) DE68906707T2 (en)
DK (1) DK174289A (en)
HU (1) HU204996B (en)
IE (1) IE62751B1 (en)
IL (1) IL89872A (en)
MY (1) MY103872A (en)
NZ (1) NZ228712A (en)
PH (1) PH25857A (en)
PT (1) PT90249B (en)
ZA (1) ZA892622B (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006547A (en) * 1990-03-19 1991-04-09 Pfizer Inc. Tenidap as an inhibitor of the release of elastase by neutrophils
US5008283A (en) * 1990-03-19 1991-04-16 Pfizer Inc. Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase
US5122534A (en) * 1991-02-08 1992-06-16 Pfizer Inc. Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
DE4111305A1 (en) * 1991-04-08 1992-10-15 Mack Chem Pharm PHARMACEUTICAL PREPARATION FOR RECTAL APPLICATION CONTAINING A 2-OXINDOL-L-CARBOXAMIDE DERIVATIVE
DE4111306A1 (en) * 1991-04-08 1992-10-15 Mack Chem Pharm PHARMACEUTICAL PREPARATIONS CONTAINING A 2-OXINDOL-L-CARBOXAMIDE DERIVATIVE AND INTENDED FOR INJECTION
US5298522A (en) * 1993-01-22 1994-03-29 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
WO1994016694A1 (en) * 1993-01-22 1994-08-04 Pfizer Inc. Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ286951A (en) * 1995-07-13 1998-02-26 Anormed Inc Substituted Under N-n-diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2-propanamine dimaleate
WO1997022605A1 (en) * 1995-12-19 1997-06-26 Pfizer Inc. Stable, long acting salts of indole derivatives for the treatment of joint diseases
EP0826685A1 (en) * 1996-08-21 1998-03-04 Pfizer Inc. Stable, long acting salts of carboxamides for the treatment of joint disease
WO2006105796A1 (en) * 2005-04-08 2006-10-12 Leo Pharma A/S Novel indolinone derivatives
EP2886541A1 (en) * 2013-12-19 2015-06-24 Sanofi Oxindole derivatives, preparation thereof and therapeutic use in the treatment of AMPK-related diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556672A (en) * 1984-03-19 1985-12-03 Pfizer Inc. 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
US4569942A (en) * 1984-05-04 1986-02-11 Pfizer Inc. N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3413572A1 (en) * 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt OXINDOL COMPOUNDS FOR TREATING EPILEPSY
EP0284612B1 (en) * 1986-01-30 1991-07-24 University of Utah Treatment of bone loss
US5036099A (en) * 1987-02-02 1991-07-30 Pfizer Inc. Anhydrous, crystalline sodium salt of 5-chloro-3-(2-thenoyl)-2-oxindole-1-carboxamide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4556672A (en) * 1984-03-19 1985-12-03 Pfizer Inc. 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
US4569942A (en) * 1984-05-04 1986-02-11 Pfizer Inc. N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
"Three Pfizer Drugs Promising; FDA Okay to Be Sought in '89", Chemical Marketing Reporter, Sep. 14, 1987, p. 7.
Autoimmunity: Basic Concepts; Systemic and Selected Organ Specific Diseases, Cruse, J. M. and Lewis, Jr., R. E., Eds., S. Karger, New York (1985), pp. 51 71. *
Autoimmunity: Basic Concepts; Systemic and Selected Organ-Specific Diseases, Cruse, J. M. and Lewis, Jr., R. E., Eds., S. Karger, New York (1985), pp. 51-71.
Bailey, J. M. et al., "Regulation of T-Lymphocyte Mitogenesis by the Leukocyte Product 15-Hydroxy-eicosatetraenoic Acid (15-HETE)", Cellular Immunology, 67, 112-120 (1982).
Bailey, J. M. et al., Regulation of T Lymphocyte Mitogenesis by the Leukocyte Product 15 Hydroxy eicosatetraenoic Acid (15 HETE) , Cellular Immunology, 67, 112 120 (1982). *
Bellanti, Joseph A., Immunology III, W. B. Saunders Co., Philadelphia (1985), Chapter 20, Part C, pp. 409 446. *
Bellanti, Joseph A., Immunology III, W. B. Saunders Co., Philadelphia (1985), Chapter 20, Part C, pp. 409-446.
Crout, J. E. et al., "Suppression of Lymphocyte Transformation After Aspirin Ingestion", N.E.J. Med., 292, 221-223 (1975).
Crout, J. E. et al., Suppression of Lymphocyte Transformation After Aspirin Ingestion , N.E.J. Med., 292, 221 223 (1975). *
F D C Reports, Sep. 14, 1987, p. 2. *
F D C Reports, Sep. 28, 1987, p. 11. *
F-D-C Reports, Sep. 14, 1987, p. 2.
F-D-C Reports, Sep. 28, 1987, p. 11.
Gordon, D. et al., "Control of Lymphokine Secretion by Prostaglandins", Nature, 262, 401-402 (1976).
Gordon, D. et al., Control of Lymphokine Secretion by Prostaglandins , Nature, 262, 401 402 (1976). *
Hanna, N. et al., "Cytokines: Targets for Novel Anti-Inflammatories: An Overview", Adv. Inflammation Res., vol. 12 (1988), pp. 11-14.
Hanna, N. et al., Cytokines: Targets for Novel Anti Inflammatories: An Overview , Adv. Inflammation Res., vol. 12 (1988), pp. 11 14. *
Kelly, J. P. et al., "Effect of Inhibitors of Arachidonic Acid Metabolism on Mitogenesis in Human Lymphocytes: Possible Role of Thromboxanes and Products of the Lipoxygenase Pathway", J. Immunology, 122, 1563-1571 (1979).
Kelly, J. P. et al., Effect of Inhibitors of Arachidonic Acid Metabolism on Mitogenesis in Human Lymphocytes: Possible Role of Thromboxanes and Products of the Lipoxygenase Pathway , J. Immunology, 122, 1563 1571 (1979). *
Kunkel, S. L. et al., "Prostaglandins and the Regulation of Immune Responses", Adv. Inflammation Res., 7, 93-109 (1984).
Kunkel, S. L. et al., "Role of Lipoxygenase Products in Murine Pulmonary Granuloma Formation", J. Clin. Invest., 74, 514-524 (1984).
Kunkel, S. L. et al., Prostaglandins and the Regulation of Immune Responses , Adv. Inflammation Res., 7, 93 109 (1984). *
Kunkel, S. L. et al., Role of Lipoxygenase Products in Murine Pulmonary Granuloma Formation , J. Clin. Invest., 74, 514 524 (1984). *
Leung, K. H. et al., "Modulation of the Development of Cell-Mediated Immunity: Possible Role of the Products of the Cyclo-oxygenase and the Lipoxygenase Pathways of Arachidonic Acid Metabolism", Int. J. Immunopharmac., 4, 195-204 (1982).
Leung, K. H. et al., Modulation of the Development of Cell Mediated Immunity: Possible Role of the Products of the Cyclo oxygenase and the Lipoxygenase Pathways of Arachidonic Acid Metabolism , Int. J. Immunopharmac., 4, 195 204 (1982). *
O Flaherty, J. T. et al., Neutrophil Aggregating Activity of Monohydroxyeicosatetraenoic Acids , A.J.P., 104, 55 62 (1981). *
O'Flaherty, J. T. et al., "Neutrophil-Aggregating Activity of Monohydroxyeicosatetraenoic Acids", A.J.P., 104, 55.62 (1981).
Pages 6 8 of the Presentation by Barry M. Bloom to Analysts of First Boston, New York City, New York on Sep. 10, 1987. *
Pages 6-8 of the Presentation by Barry M. Bloom to Analysts of First Boston, New York City, New York on Sep. 10, 1987.
Three Pfizer Drugs Promising; FDA Okay to Be Sought in 89 , Chemical Marketing Reporter, Sep. 14, 1987, p. 7. *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006547A (en) * 1990-03-19 1991-04-09 Pfizer Inc. Tenidap as an inhibitor of the release of elastase by neutrophils
US5008283A (en) * 1990-03-19 1991-04-16 Pfizer Inc. Use of tenidap to inhibit activation of collagenase and to inhibit the activity of myeloperoxidase
US5122534A (en) * 1991-02-08 1992-06-16 Pfizer Inc. Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
EP0498588B1 (en) * 1991-02-08 1995-04-26 Pfizer Inc. Use of tenidap to reduce total serum cholesterol, LDL cholesterol and triglycerides
DE4111305A1 (en) * 1991-04-08 1992-10-15 Mack Chem Pharm PHARMACEUTICAL PREPARATION FOR RECTAL APPLICATION CONTAINING A 2-OXINDOL-L-CARBOXAMIDE DERIVATIVE
DE4111306A1 (en) * 1991-04-08 1992-10-15 Mack Chem Pharm PHARMACEUTICAL PREPARATIONS CONTAINING A 2-OXINDOL-L-CARBOXAMIDE DERIVATIVE AND INTENDED FOR INJECTION
US5298522A (en) * 1993-01-22 1994-03-29 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
EP0608058A1 (en) * 1993-01-22 1994-07-27 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent
WO1994016694A1 (en) * 1993-01-22 1994-08-04 Pfizer Inc. Lysine salt of 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
AU700932B2 (en) * 1995-04-05 1999-01-14 Pfizer Inc. Pharmaceutical agents for the treatment of Alzheimer's disease

Also Published As

Publication number Publication date
ZA892622B (en) 1990-11-28
AU3271289A (en) 1989-10-19
PT90249A (en) 1989-11-10
DE68906707D1 (en) 1993-07-01
DK174289D0 (en) 1989-04-12
EP0337628A2 (en) 1989-10-18
JPH01311022A (en) 1989-12-15
KR920002328B1 (en) 1992-03-21
IE62751B1 (en) 1995-02-22
PT90249B (en) 1994-06-30
CA1324762C (en) 1993-11-30
IL89872A0 (en) 1989-12-15
AU601326B2 (en) 1990-09-06
PH25857A (en) 1991-12-02
HU204996B (en) 1992-03-30
MY103872A (en) 1993-09-30
IE891171L (en) 1989-10-13
IL89872A (en) 1994-06-24
HUT52376A (en) 1990-07-28
EP0337628A3 (en) 1991-01-02
DE68906707T2 (en) 1993-09-16
DK174289A (en) 1989-10-16
NZ228712A (en) 1997-02-24
ATE89725T1 (en) 1993-06-15
KR890015740A (en) 1989-11-25
EP0337628B1 (en) 1993-05-26

Similar Documents

Publication Publication Date Title
US4853409A (en) 3-substituted-2-oxindole-1-carboxamides for suppressing T-cell function
US4794114A (en) Inhibition of interleukin-1 production by monocytes and/or macrophages
CA1324761C (en) 3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis
KR940011245B1 (en) Pharmaceutical composition containing tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
EP0610444B1 (en) Use of a polyhydroxybenzamide or a derivative thereof in the manufacture of a medicament for treating viral infectious diseases
EP0413329A2 (en) 5-Methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic acid anilides for the treatment of ocular diseases
KR910700230A (en) New hydroxylamine derivatives
EP0543855A1 (en) Use of aryl hydroxyurea compounds for the treatment of atherosclerosis
US5006547A (en) Tenidap as an inhibitor of the release of elastase by neutrophils
EP0425109B1 (en) 3-Substituted-2-oxindole derivatives as inhibitors of interleukin-1 biosynthesis
IL92586A (en) Derivatives of 5-hydroxy and 5-methoxy 2-amino-pyrimidines as inhibitors of interleukin-1 production
BG100385A (en) The use of benzidamine for the treatment of pathological conditions caused by tumournecrotic factor
US5461072A (en) Use of aryl hydroxyurea compounds for the treatment of atherosclerosis
CA1162856A (en) Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5- methoxy-2-methyl-1h-indole-3-acetic acid
US4423060A (en) Aldose reductase inhibition by 1-methyl-5-(4-methylbenzoyl)-1H-pyrrole-2-acetic acid
JPH0859464A (en) 3-substituted-2-oxyndoles as inhibiting substance of virus reproduction
NZ235638A (en) The use of indole derivatives for treating interleukin-1 related disorders
KR890001561A (en) Pharmaceutical preparations for the treatment of bacterial infections

Legal Events

Date Code Title Description
AS Assignment

Owner name: PFIZER INC., 235 EAST 42ND STREET, NEW YORK, NEW Y

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:SHOWELL, HENRY J.;REEL/FRAME:004898/0630

Effective date: 19880413

Owner name: PFIZER INC., A CORP. OF DE.,NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SHOWELL, HENRY J.;REEL/FRAME:004898/0630

Effective date: 19880413

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12